New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present).

IF 4.7 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2026-07-01 Epub Date: 2026-06-19 DOI:10.1080/13543776.2026.2689602

Martina Franzin, Marianna Lucafò, Debora Curci, Giuliana Decorti, Gabriele Stocco

{"title":"New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present).","authors":"Martina Franzin, Marianna Lucafò, Debora Curci, Giuliana Decorti, Gabriele Stocco","doi":"10.1080/13543776.2026.2689602","DOIUrl":null,"url":null,"abstract":"Introduction: Selective glucocorticoid receptor modulators (SGRM) have emerged as promising agents to counteract glucocorticoid‑driven chemoresistance, immune suppression, and poor prognosis in solid tumors by modulating glucocorticoid receptor (GR) signaling without losing anticancer immune activity.Areas covered: This review provides a focused update to a previous patent review on SGRM (2014-2020) by summarizing Espacenet-indexed patent applications published between 2020 and 30 April 2026 (PCT/US2020/055498, PCT/US2021/017259, PCT/US2022/042475) describing anticancer strategies.Expert opinion: Collectively, these patents support SGRM in addition to cytotoxic and immunotherapeutic regimens in solid tumors. Preclinical and early‑phase clinical evidence (phase I/II) describes how GR antagonism, continuously or intermittently, lowers elevated neutrophil-to-lymphocyte ratio (NLR), modulates GR‑target transcriptional signatures, and enhances responses to nab‑paclitaxel and anti‑PD‑1 antibodies. Key limitations of these patents consist of evidence based on still limited clinical sample sizes, requiring confirmation in phase III trials, and on benefit enriched in biologically defined subpopulations. From a clinical perspective, these agents could be realistically integrated into anticancer protocols, as they work synergistically with other chemotherapeutics.","PeriodicalId":12314,"journal":{"name":"Expert Opinion on Therapeutic Patents","volume":" ","pages":"665-677"},"PeriodicalIF":4.7000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Therapeutic Patents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543776.2026.2689602","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Selective glucocorticoid receptor modulators (SGRM) have emerged as promising agents to counteract glucocorticoid‑driven chemoresistance, immune suppression, and poor prognosis in solid tumors by modulating glucocorticoid receptor (GR) signaling without losing anticancer immune activity.

Areas covered: This review provides a focused update to a previous patent review on SGRM (2014-2020) by summarizing Espacenet-indexed patent applications published between 2020 and 30 April 2026 (PCT/US2020/055498, PCT/US2021/017259, PCT/US2022/042475) describing anticancer strategies.

Expert opinion: Collectively, these patents support SGRM in addition to cytotoxic and immunotherapeutic regimens in solid tumors. Preclinical and early‑phase clinical evidence (phase I/II) describes how GR antagonism, continuously or intermittently, lowers elevated neutrophil-to-lymphocyte ratio (NLR), modulates GR‑target transcriptional signatures, and enhances responses to nab‑paclitaxel and anti‑PD‑1 antibodies. Key limitations of these patents consist of evidence based on still limited clinical sample sizes, requiring confirmation in phase III trials, and on benefit enriched in biologically defined subpopulations. From a clinical perspective, these agents could be realistically integrated into anticancer protocols, as they work synergistically with other chemotherapeutics.

查看原文本刊更多论文

抗癌糖皮质激素受体调节剂的新见解：专利审查（2020年至今）。

选择性糖皮质激素受体调节剂（SGRM）通过调节糖皮质激素受体（GR）信号而不丧失抗癌免疫活性，已成为一种有前景的药物，可在实体瘤中对抗糖皮质激素驱动的化疗耐药、免疫抑制和不良预后。本次审查通过总结2020年至2026年4月30日期间公布的espacenet检索专利申请（PCT/US2020/055498、PCT/US2021/017259、PCT/US2022/042475），对先前的SGRM专利审查（2014-2020）进行了重点更新，描述了抗癌策略。专家意见：总的来说，这些专利除了支持细胞毒性和免疫治疗方案外，还支持实体肿瘤的SGRM。临床前和早期临床证据（I/II期）描述了GR拮抗剂如何持续或间歇性地降低升高的中性粒细胞与淋巴细胞比率（NLR），调节GR靶点转录特征，并增强对紫杉醇和抗PD - 1抗体的反应。这些专利的主要限制包括基于仍然有限的临床样本量的证据，需要在III期试验中确认，以及在生物学定义的亚群中丰富的益处。从临床角度来看，这些药物可以实际地整合到抗癌方案中，因为它们与其他化疗药物协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.